Drugs in Human Milk Part 1: Practical and Analytical Considerations in Measuring Drugs and Metabolites in Human Milk Osama Y. AlshogranPrerna DodejaRaman Venkataramanan Review Article 15 May 2024 Pages: 561 - 588
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review J. van GendtR. EmausPaola Mian Systematic Review Open access 07 April 2024 Pages: 589 - 622
Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review Keng Wah FoongSook Hui ChawPui San Loh Systematic Review 04 May 2024 Pages: 623 - 643
Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole Anouk M. E. JansenKim SnijdelaarRob ter Heine Original Research Article Open access 26 March 2024 Pages: 645 - 656
Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling Krina MehtaPavel BalazkiJ. G. Coen van Hasselt Original Research Article Open access 26 March 2024 Pages: 657 - 668
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors Abhishek G. SatheIndrajeet SinghAhmed A. Othman Original Research Article Open access 05 April 2024 Pages: 669 - 681
Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration Julia E. M. van DommelenHeleen GrootjansMaaike A. Sikma Original Research Article Open access 06 April 2024 Pages: 683 - 693
Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents Conor J. O’HanlonAnita SumpterJacqueline A. Hannam Original Research Article Open access 13 April 2024 Pages: 695 - 706
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model Yulan QiMing Liang ChanJoshua Henshaw Original Research Article Open access 23 April 2024 Pages: 707 - 719
Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers Lisanne A. H. BeversAnne E. M. KamphuisAngela Colbers Original Research Article Open access 04 April 2024 Pages: 721 - 728
Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers Lisanne A. H. BeversAnne E. M. KamphuisAngela Colbers Correction Open access 02 May 2024 Pages: 729 - 730
Comment on “Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies” and “High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints” Leping KongJan-Willem C. AlffenaarSophie L. Stocker Letter to the Editor 04 April 2024 Pages: 731 - 733